Key result
Ivabradine combined with trimetazidine reduced left ventricular end-diastolic pressure and inhibited myocardial fibrosis markers in rats with chronic heart failure.
Why the study?
The study explored the effects of ivabradine hydrochloride and trimetazidine on myocardial fibrosis in rats with chronic heart failure.
Does ivabradine combined with trimetazidine improve hemodynamics and reduce myocardial fibrosis markers in a rat model of chronic heart failure?
Does ivabradine combined with trimetazidine improve hemodynamics and reduce myocardial fibrosis markers in a rat model of chronic heart failure?
Answers are grounded in this paper and cite their sources.
The combination of ivabradine and trimetazidine synergistically improves hemodynamics and attenuates myocardial fibrosis markers in a rat model of chronic heart failure.
Effects of ivabradine hydrochloride (Iva) and trimetazidine on myocardial fibrosis (MF) in rats with chronic heart failure (CHF) werφe explored. Fifty Wistar rats were randomly divided into sham operation, model, Iva, trimetazidine and combined drug group with 10 rats each. All rats except those in sham operation group were subjected to establish CHF model by constricting the abdominal aorta. After successful modeling, rats in the sham operation and model group received normal saline (10 mg/kg) gavage daily, the Iva group received Iva (10 mg/kg) gavage, the trimetazidine group received trimetazidine (10 mg/kg) gavage, and the combined drug group were given Iva (10 mg/kg) and trimetazidine (10 mg/kg) gavage for 12 weeks. The changes of hemodynamic indexes and heart rate, connective tissue growth factor (CTGF) and superoxide dismutase (SOD) levels as well as transforming growth factor β1 (TGF-β1) and collagen I (COL-I) expression levels in myocardial tissue of each group were detected. Compared with sham operation group, the left ventricular end-diastolic pressure (LVEDP) level, CTGF expression, TGF-β1 mRNA and COL-I mRNA expression levels in model group increased significantly, but the ± dp/dtmax and SOD content in myocardial tissue decreased significantly. Compared with model group, the LVEDP level, CTGF expression, TGF-β1 mRNA and COL-I mRNA expression levels in Iva group, trimetazidine group and combined drugs decreased significantly, but the ± dp/dtmax and the SOD content in myocardial tissue increased significantly (P<0.05). Changes in the combined drug group were the most notable (P<0.05). Iva combined with trimetazidine reduces LVEDP in rat with CHF, increases SOD content, and inhibits CTGF expression and TGF-β1 and COL-I expression levels in myocardial tissues, thus achieving the inhibitory effect on MF.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2019) studied Chronic heart failure with myocardial fibrosis (n=50). Ivabradine hydrochloride combined with trimetazidine vs. Normal saline (model group) was evaluated on Left ventricular end-diastolic pressure (LVEDP) (p=<0.001). Ivabradine combined with trimetazidine reduced left ventricular end-diastolic pressure and inhibited myocardial fibrosis markers in rats with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: